Stock Fundamentals

AI Research Report

Generate a comprehensive financial analysis report powered by AI

CRL.US Logo

CRL.US - Current Price

$218.82

Company Information

Company Name
Charles River Laboratories
Sector
Healthcare
Industry
Diagnostics & Research
Exchange
NYSE
ISIN: US1598641074
CIK: 0001100682
CUSIP: 159864107
Currency: USD
Full Time Employees: 18,700
Phone: 781 222 6000
Fiscal Year End: December
IPO Date: Jun 23, 2000
Description:

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It utilizes Logica, a platform offering from Valo Health, to identify advanceable small molecule leads. It provides contract vivarium operation services to biopharmaceutical clients. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. Additionally, It has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. The company was founded in 1947 and is headquartered in Wilmington, Mas

Address:

251 Ballardvale Street, Wilmington, MA, United States, 01887

Directors & Officers

Name Title Year Born
Mr. James C. Foster J.D. Chairman, President & CEO 1951
Ms. Birgit Girshick Corporate Executive VP & COO 1971
Mr. Joseph W. LaPlume J.D. Corporate Executive Vice President of Corporate Development & Strategy 1974
Ms. Victoria L. Creamer Corporate Executive VP & Chief People Officer 1970
Mr. Michael Gunnar Knell Interim CFO, Corporate Senior VP & Chief Accounting Officer 1977
Prof. Julie Frearson Ph.D. Corporate Senior VP & Chief Scientific Officer NA
Mr. Mark Mintz Corporate EVP, Chief Information Officer & Global Shared Services NA
Mr. Todd Spencer Corporate Vice President of Investor Relations NA
Mr. Matthew L. Daniel J.D. Corporate Senior VP, General Counsel, Corporate Secretary & Chief Compliance Officer NA
Ms. Amy E. Cianciaruso Corporate Senior Vice President, Chief Communications Officer & Government Relations NA

Shares Statistics

Shares Outstanding: 49.22M
Shares Float: 48.70M
% Insiders: 100.20%
% Institutions: 10,790.30%
Short % Float: 5.63%

Valuation Metrics

Enterprise Value: $13.29B
Trailing P/E: 0.00
Forward P/E: 20.53

Financial Highlights

Market Cap: $10.77B
EBITDA: $884.89M
PEG Ratio: $0.16
Book Value: $69.20
Earnings/Share: $-1.53
Profit Margin: -2.05%
Operating Margin: 15.04%
ROA (TTM): 4.34%
ROE (TTM): -2.19%
Revenue (TTM): $4.02B
Revenue/Share (TTM): $80.40
Earnings Growth (YOY): -17.30%
Revenue Growth (YOY): -0.50%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income

Operating Expenses

Balance Sheet Overview

Earnings Per Share (EPS)

Earnings History

Date EPS Actual EPS Estimate Difference Surprise %
Sep 30, 2025 2.43 2.35 N/A 340.43%
Jun 30, 2025 3.12 2.55 N/A 2,235.29%
Mar 31, 2025 2.34 2.07 N/A 1,304.35%
Dec 31, 2024 2.66 2.53 N/A 513.83%
Sep 30, 2024 2.59 2.42 N/A 702.48%
Jun 30, 2024 2.80 2.39 N/A 1,715.48%
Mar 31, 2024 2.27 2.07 N/A 966.18%
Dec 31, 2023 2.46 2.40 N/A 250.00%
Sep 30, 2023 2.72 2.37 N/A 1,476.79%
Jun 30, 2023 2.69 2.64 N/A 189.39%
Mar 31, 2023 2.78 2.59 N/A 733.59%
Dec 31, 2022 2.98 2.75 N/A 836.36%
Sep 30, 2022 2.63 2.50 N/A 520.00%
Jun 30, 2022 2.77 2.73 N/A 146.52%
Mar 31, 2022 2.75 2.72 N/A 110.29%
Dec 31, 2021 2.49 2.43 N/A 246.91%
Sep 30, 2021 2.70 2.58 N/A 465.12%
Jun 30, 2021 2.61 2.38 N/A 966.39%
Mar 31, 2021 2.53 2.19 N/A 1,552.51%
Dec 31, 2020 2.39 2.11 N/A 1,327.01%
Sep 30, 2020 2.33 1.80 N/A 2,944.44%
Jun 30, 2020 1.58 1.26 N/A 2,539.68%
Mar 31, 2020 1.84 1.48 N/A 2,432.43%
Dec 31, 2019 2.01 1.83 N/A 983.61%
Sep 30, 2019 1.69 1.63 N/A 368.10%
Jun 30, 2019 1.63 1.55 N/A 516.13%
Mar 31, 2019 1.40 1.38 N/A 144.93%
Dec 31, 2018 1.49 1.40 N/A 642.86%
Sep 30, 2018 1.53 1.38 N/A 1,086.96%
Jun 30, 2018 1.62 1.46 N/A 1,095.89%
Mar 31, 2018 1.38 1.26 N/A 952.38%
Dec 31, 2017 1.40 1.25 N/A 1,200.00%
Sep 30, 2017 1.30 1.22 N/A 655.74%
Jun 30, 2017 1.29 1.22 N/A 573.77%
Mar 31, 2017 1.29 1.14 N/A 1,315.79%
Dec 31, 2016 1.21 1.11 N/A 900.90%
Sep 30, 2016 1.18 1.13 N/A 442.48%
Jun 30, 2016 1.20 1.10 N/A 909.09%
Mar 31, 2016 0.98 0.90 N/A 888.89%
Dec 31, 2015 1.00 0.94 N/A 638.30%
Sep 30, 2015 1.03 0.94 N/A 957.45%
Jun 30, 2015 0.96 0.97 N/A -103.09%
Mar 31, 2015 0.79 0.82 N/A -365.85%
Dec 31, 2014 0.81 0.71 N/A 1,408.45%
Sep 30, 2014 0.86 0.80 N/A 750.00%
Jun 30, 2014 0.97 0.82 N/A 1,829.27%
Mar 31, 2014 0.82 0.74 N/A 1,081.08%
Dec 31, 2013 0.73 0.68 N/A 735.29%
Sep 30, 2013 0.79 0.70 N/A 1,285.71%
Jun 30, 2013 0.73 0.71 N/A 281.69%
Mar 31, 2013 0.69 0.71 N/A -281.69%
Dec 31, 2012 0.64 0.60 N/A 666.67%
Sep 30, 2012 0.65 0.62 N/A 483.87%
Jun 30, 2012 0.75 0.66 N/A 1,363.64%
Mar 31, 2012 0.70 0.65 N/A 769.23%
Dec 31, 2011 0.69 0.56 N/A 2,321.43%
Sep 30, 2011 0.57 0.58 N/A -172.41%
Jun 30, 2011 0.70 0.60 N/A 1,666.67%
Mar 31, 2011 0.61 0.55 N/A 1,090.91%
Dec 31, 2010 0.60 0.49 N/A 2,244.90%
Sep 30, 2010 0.45 0.49 N/A -816.33%
Jun 30, 2010 0.49 0.50 N/A -200.00%
Mar 31, 2010 0.45 0.47 N/A -425.53%
Dec 31, 2009 0.49 0.44 N/A 1,136.36%
Sep 30, 2009 0.65 0.60 N/A 833.33%
Jun 30, 2009 0.66 0.58 N/A 1,379.31%
Mar 31, 2009 0.58 0.53 N/A 943.40%
Dec 31, 2008 0.59 0.55 N/A 727.27%
Sep 30, 2008 0.76 0.75 N/A 133.33%
Jun 30, 2008 0.79 0.73 N/A 821.92%
Mar 31, 2008 0.72 0.69 N/A 434.78%
Dec 31, 2007 0.65 0.63 N/A 317.46%
Sep 30, 2007 0.69 0.62 N/A 1,129.03%
Jun 30, 2007 0.64 0.62 N/A 322.58%
Mar 31, 2007 0.64 0.61 N/A 491.80%
Dec 31, 2006 0.58 0.58 N/A 0.00%
Sep 30, 2006 0.56 0.54 N/A 370.37%
Jun 30, 2006 0.57 0.53 N/A 754.72%
Mar 31, 2006 0.50 0.57 N/A -1,228.07%
Dec 31, 2005 0.59 0.57 N/A 350.88%
Sep 30, 2005 0.57 0.57 N/A 0.00%
Jun 30, 2005 0.59 0.60 N/A -166.67%
Mar 31, 2005 0.55 0.55 N/A 0.00%
Dec 31, 2004 0.48 0.47 N/A 212.77%
Sep 30, 2004 0.51 0.49 N/A 408.16%
Jun 30, 2004 0.52 0.49 N/A 612.24%
Mar 31, 2004 0.47 0.44 N/A 681.82%
Dec 31, 2003 0.42 0.38 N/A 1,052.63%
Sep 30, 2003 0.40 0.40 N/A 0.00%
Jun 30, 2003 0.42 0.41 N/A 243.90%
Mar 31, 2003 0.41 0.40 N/A 250.00%
Dec 31, 2002 0.36 0.36 N/A 0.00%
Sep 30, 2002 0.39 0.36 N/A 833.33%
Jun 30, 2002 0.36 0.32 N/A 1,250.00%
Mar 31, 2002 0.31 0.27 N/A 1,481.48%
Dec 31, 2001 0.24 0.24 N/A 0.00%
Sep 30, 2001 0.26 0.23 N/A 1,304.35%
Jun 30, 2001 0.24 0.21 N/A 1,428.57%
Mar 31, 2001 0.19 0.17 N/A 1,176.47%
Dec 31, 2000 0.11 0.09 N/A 2,222.22%
Sep 30, 2000 0.12 0.08 N/A 5,000.00%
Jun 30, 2000 0.18 0.08 N/A 12,500.00%

Balance Sheet (Yearly)

Date Cash Total Debt Total Assets Total Liabilities Total Equity
2024-12-31 $194.61M $N/A $7.53B $4.02B $3.46B
2023-12-31 $276.77M $N/A $8.20B $4.54B $3.60B
2022-12-31 $233.91M $N/A $7.60B $4.58B $2.98B
2021-12-31 $245.24M $N/A $7.02B $4.43B $2.53B
2020-12-31 $228.42M $N/A $5.49B $3.35B $2.11B
2019-12-31 $238.01M $N/A $4.69B $3.03B $1.63B
2018-12-31 $195.44M $N/A $3.86B $2.52B $1.32B
2017-12-31 $163.79M $N/A $2.93B $1.87B $1.05B
2016-12-31 $117.63M $N/A $2.71B $1.86B $836.77M
2015-12-31 $117.95M $N/A $2.07B $1.30B $733.07M
2014-12-31 $160.02M $N/A $1.89B $1.18B $672.20M
2013-12-31 $155.93M $N/A $1.64B $979.96M $640.98M
2012-12-31 $109.69M $N/A $1.59B $983.14M $600.81M
2011-12-31 $68.91M $N/A $1.56B $1.03B $527.36M
2010-12-31 $179.16M $N/A $1.73B $1.04B $687.42M
2009-12-31 $182.57M $N/A $2.20B $830.27M $1.37B
2008-12-31 $243.59M $N/A $2.16B $960.47M $1.20B
2007-12-31 $225.45M $N/A $2.81B $941.57M $1.86B
2006-12-31 $175.38M $N/A $2.56B $953.11M $1.60B
2005-12-31 $114.82M $N/A $2.54B $701.48M $1.83B
2004-12-31 $207.57M $N/A $2.63B $1.14B $1.47B
2003-12-31 $182.33M $N/A $799.55M $324.76M $464.62M
2002-12-31 $122.51M $N/A $701.34M $325.40M $357.38M
2001-12-31 $58.27M $N/A $571.36M $268.86M $289.51M
2000-12-31 $33.13M $N/A $410.61M $280.35M $116.93M
1999-12-31 $15.01M $N/A $363.06M $472.89M $-110.14M
1998-12-31 $24.81M $N/A $234.25M $65.69M $168.26M

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Aug 18, 2025 N/A N/A N/A N/A N/A N/A
Aug 07, 2025 N/A N/A N/A N/A N/A N/A
May 15, 2025 N/A N/A N/A N/A N/A N/A
May 14, 2025 N/A N/A N/A N/A N/A N/A
May 13, 2025 N/A N/A N/A N/A N/A N/A
May 12, 2025 N/A N/A N/A N/A N/A N/A
May 08, 2025 N/A N/A N/A N/A N/A N/A
Apr 15, 2025 N/A N/A N/A N/A N/A N/A
Apr 09, 2025 N/A N/A N/A N/A N/A N/A
Apr 08, 2025 N/A N/A N/A N/A N/A N/A
Feb 20, 2025 N/A N/A N/A N/A N/A N/A
Feb 20, 2025 N/A N/A N/A N/A N/A N/A
Feb 20, 2025 N/A N/A N/A N/A N/A N/A
Jan 15, 2025 N/A N/A N/A N/A N/A N/A
Nov 07, 2024 N/A N/A N/A N/A N/A N/A

Watchlist

0

No stocks in watchlist